Terms: = Skin cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
120 results:
1. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
[TBL] [Abstract] [Full Text] [Related]
2. Mi-2β promotes immune evasion in melanoma by activating ezh2 methylation.
Li C; Wang Z; Yao L; Lin X; Jian Y; Li Y; Zhang J; Shao J; Tran PD; Hagman JR; Cao M; Cong Y; Li HY; Goding CR; Xu ZX; Liao X; Miao X; Cui R
Nat Commun; 2024 Mar; 15(1):2163. PubMed ID: 38461299
[TBL] [Abstract] [Full Text] [Related]
3. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract] [Full Text] [Related]
4. Combined Inhibition of ezh2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract] [Full Text] [Related]
5. 3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
Hosokawa M; Tetsumoto S; Yasui M; Kono Y; Ogawara KI
Biochem Biophys Res Commun; 2023 Oct; 677():26-30. PubMed ID: 37542772
[TBL] [Abstract] [Full Text] [Related]
6. Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus.
Khattri M; Amako Y; Gibbs JR; Collura JL; Arora R; Harold A; Li MY; Harms PW; Ezhkova E; Shuda M
Tumour Virus Res; 2023 Dec; 16():200264. PubMed ID: 37244352
[TBL] [Abstract] [Full Text] [Related]
7. Distinct Regulation of ezh2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma.
Durand MA; Drouin A; Mouchard A; Durand L; Esnault C; Berthon P; Tallet A; Le Corre Y; Hainaut-Wierzbicka E; Blom A; Saiag P; Beneton N; Bens G; Nardin C; Aubin F; Dinulescu M; Collin C; Fromont-Hankard G; Cribier B; Laurent-Roussel S; Cokelaere K; Houben R; Schrama D; Peixoto P; Hervouet E; Bachiri K; Kantar D; Coyaud E; Guyétant S; Samimi M; Touzé A; Kervarrec T
J Invest Dermatol; 2023 Oct; 143(10):1937-1946.e7. PubMed ID: 37037414
[TBL] [Abstract] [Full Text] [Related]
8. Pharmacological inhibition of ezh2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo.
Zhu Y; Zhang L; Song X; Zhang Q; Wang T; Xiao H; Yu L
Biochem Pharmacol; 2023 Apr; 210():115493. PubMed ID: 36898415
[TBL] [Abstract] [Full Text] [Related]
9. Resistance to BRAF Inhibitors: ezh2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
[TBL] [Abstract] [Full Text] [Related]
10. ezh2
Zimmerman SM; Nixon SJ; Chen PY; Raj L; Smith SR; Paolini RL; Lin PN; Souroullas GP
Oncogene; 2022 Nov; 41(46):4983-4993. PubMed ID: 36220978
[TBL] [Abstract] [Full Text] [Related]
11. SHR2554, an ezh2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
Song Y; Liu Y; Li ZM; Li L; Su H; Jin Z; Zuo X; Wu J; Zhou H; Li K; He C; Zhou J; Qi J; Hao S; Cai Z; Li Y; Wang W; Zhang X; Zou J; Zhu J
Lancet Haematol; 2022 Jul; 9(7):e493-e503. PubMed ID: 35772429
[TBL] [Abstract] [Full Text] [Related]
12. Contribution and clinical relevance of germline variation to the cancer transcriptome.
Pereira B; Labrot E; Durand E; Korn JM; Kauffmann A; Campbell CD
BMC Cancer; 2022 Jun; 22(1):675. PubMed ID: 35725412
[TBL] [Abstract] [Full Text] [Related]
13. Prenatal exposure to arsenic promotes sterile inflammation through the Polycomb repressive element ezh2 and accelerates skin tumorigenesis in mouse.
Sharma V; Gangopadhyay S; Shukla S; Chauhan A; Singh S; Singh RD; Tiwari R; Singh D; Srivastava V
Toxicol Appl Pharmacol; 2022 May; 443():116004. PubMed ID: 35364107
[TBL] [Abstract] [Full Text] [Related]
14. Merkel Cell Carcinoma Sensitivity to ezh2 Inhibition Is Mediated by SIX1 Derepression.
Gartin AK; Frost TC; Cushman CH; Leeper BA; Gokhale PC; DeCaprio JA
J Invest Dermatol; 2022 Oct; 142(10):2783-2792.e15. PubMed ID: 35331717
[TBL] [Abstract] [Full Text] [Related]
15. ezh2-CCF-cGAS Axis Promotes Breast cancer Metastasis.
Duan D; Shang M; Han Y; Liu J; Liu J; Kong SH; Hou J; Huang B; Lu J; Zhang Y
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163710
[TBL] [Abstract] [Full Text] [Related]
16. Dual Targeting with ezh2 Inhibitor and STING Agonist to Treat Melanoma.
Emran AA; Fisher DE
J Invest Dermatol; 2022 Apr; 142(4):1004-1006. PubMed ID: 35131084
[TBL] [Abstract] [Full Text] [Related]
17. Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion.
Fane ME; Chhabra Y; Spoerri L; Simmons JL; Ludwig R; Bonvin E; Goding CR; Sturm RA; Boyle GM; Haass NK; Piper M; Smith AG
J Invest Dermatol; 2022 Jul; 142(7):1845-1857. PubMed ID: 34958806
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic and predictive value of ezh2 expression and the tumor immune microenvironment in Merkel cell carcinoma.
Acikalin A; Bagir E; Paydas S
Pol J Pathol; 2021; 72(2):140-147. PubMed ID: 34706521
[TBL] [Abstract] [Full Text] [Related]
19. DNA-methylation patterns imply a common cellular origin of virus- and UV-associated Merkel cell carcinoma.
Gravemeyer J; Spassova I; Verhaegen ME; Dlugosz AA; Hoffmann D; Lange A; Becker JC
Oncogene; 2022 Jan; 41(1):37-45. PubMed ID: 34667274
[TBL] [Abstract] [Full Text] [Related]
20. ezh2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
[TBL] [Abstract] [Full Text] [Related]
[Next]
